Late Wednesday, Illumina (ILMN) reported adjusted earnings of 32 cents per share on $1.18 billion in second-quarter gross sales. In response, ILMN inventory plunged.
X
On common, analysts surveyed by FactSet anticipated Illumina to earn 2 cents per share and report $1.16 billion in gross sales.
Within the year-earlier interval, the DNA-sequencing large reported 57 cents in earnings per share and had $1.16 billion in gross sales.
For the 12 months, Illumina predicted adjusted earnings of 75 cents to 90 cents per share and 1% gross sales progress. ILMN inventory analysts predicted earnings of $1.27 a share on almost $4.9 billion in gross sales.
The corporate cautioned gross sales within the second 12 months will probably be negatively impacted by buyer warning, a slower restoration in China and a bigger decline in consumable devices as clients transfer to Illumina’s new DNA-reading system, NovaSeq X.
In after-hours buying and selling on the inventory market right now, ILMN inventory dropped 5.9% to 173.70.
Extra to comply with.
Comply with Allison Gatlin on Twitter at @IBD_AGatlin.
YOU MAY ALSO LIKE:
Eli Lilly Has A Huge Stake In Weight Loss And Alzheimer’s Medication; However Is The Inventory A Purchase?
Mirati Rockets 31% On A Bevy Of Information In Most cancers, A $300 Million Deal And Its CEO Exit
IBD Inventory Of The Day: See How To Discover, Monitor And Purchase The Finest Shares
Be taught How To Time The Market With IBD’s ETF Market Technique
Get Well timed Purchase & Promote Alerts With IBD Leaderboard